The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

pipelinetherapeutics.com

Founded Year

2017

Stage

Series C | Alive

Total Raised

$110M

Last Raised

$80M | 1 yr ago

About Pipeline Therapeutics

Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecules for neuroregeneration.

Pipeline Therapeutics Headquarter Location

10578 Science Center Drive Ste. 200

San Diego, California, 92121,

United States

858-333-5280

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Pipeline Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Pipeline Therapeutics is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Pipeline Therapeutics Patents

Pipeline Therapeutics has filed 5 patents.

The 3 most popular patent topics include:

  • Audiology
  • Auditory system
  • Ear
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/12/2017

2/23/2021

Auditory system, Ear, Audiology, Hearing, Ear procedures

Grant

Application Date

12/12/2017

Grant Date

2/23/2021

Title

Related Topics

Auditory system, Ear, Audiology, Hearing, Ear procedures

Status

Grant

Latest Pipeline Therapeutics News

Pipeline Therapeutics to Present at Multiple Investor Conferences in May 2022

May 11, 2022

May 11, 2022 04:05 PM Eastern Daylight Time SAN DIEGO--( BUSINESS WIRE )--Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today that company management will present at the following investor conferences: 2022 RBC Capital Markets Global Healthcare Conference Wednesday, May 18, 2022 at 8:00 am ET UBS Global Healthcare Conference About Pipeline Therapeutics Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair. The Company has a broad pipeline of programs to address CNS and neuro-otology conditions. Its flagship program, PIPE-307, has completed a Phase 1 clinical trial in healthy volunteers and has received IND clearance from the FDA to initiate a Phase 1b/2a trial in relapsing-remitting MS patients. For more information, please visit www.pipelinetherapeutics.com and engage with us on LinkedIn. Contacts

Pipeline Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Pipeline Therapeutics Rank

  • When was Pipeline Therapeutics founded?

    Pipeline Therapeutics was founded in 2017.

  • Where is Pipeline Therapeutics's headquarters?

    Pipeline Therapeutics's headquarters is located at 10578 Science Center Drive, San Diego.

  • What is Pipeline Therapeutics's latest funding round?

    Pipeline Therapeutics's latest funding round is Series C.

  • How much did Pipeline Therapeutics raise?

    Pipeline Therapeutics raised a total of $110M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.